Introduction
============

In the growing field of personalised medicine, the increasing number of molecular targets for individualised therapies requires the analysis of numerous, potential genetic alterations, which is becoming a challenge in terms of workload, tissue availability, as well as costs ([@b1-ijmm-36-05-1233]). For non-small cell lung cancer (NSCLC), molecular analysis has shifted from the analysis of the epidermal growth factor receptor (*EGFR*) mutation status to the analysis of additional gene target regions, including resistance mutations and gene fusion events ([@b2-ijmm-36-05-1233]).

Taking these developments into account, massive parallel sequencing (MPS) has come into focus, as it allows rapid, comprehensive and cost-effective mutation testing for routine molecular pathological diagnostics, even on small formalin-fixed, paraffin-embedded (FFPE) biopsies ([@b3-ijmm-36-05-1233]--[@b6-ijmm-36-05-1233]). However, the implementation of MPS platforms into routine diagnostics raises questions about feasibility, sensitivity and specificity, as the results of mutation testing are the basis for therapeutic decision making ([@b1-ijmm-36-05-1233],[@b7-ijmm-36-05-1233]). The ever-increasing pace of MPS adoption presents enormous challenges, in terms of data processing, storage, management and interpretation, as well as sequencing quality control, which impede the translation of research into clinical practice ([@b8-ijmm-36-05-1233],[@b9-ijmm-36-05-1233]).

Additionally, the preanalytical steps are important to consider: the manual macrodissection of selected tumour areas has become a standard procedure in molecular pathology and is a powerful tool to reduce false negative results resulting from wild-type contamination ([@b10-ijmm-36-05-1233]). Selecting the right tumour area influences not only the result of the analysis, but also the allele frequency, the value of which is pivotal when reporting diagnostic findings ([@b11-ijmm-36-05-1233]). Automated DNA extraction systems are helpful in a routine laboratory with respect to expenditure of time, sample tracking and reproducible sample quality. In addition, an accurate and reliable DNA quantification system is necessary for good and constant MPS performance ([@b12-ijmm-36-05-1233]).

In the present study, we compared three different MPS platforms: PGM Ion Torrent™ from Life Technologies™, MiSeq™ from Illumina^®^ and GS Junior from Roche. We used lung cancer samples, obtained from the clinical setting, with a known *EGFR* and *KRAS* mutation status. Samples included large tumour resections, as well as small fine needle biopsies. In our comparison, three different multiplex primer panels, tailored to the needs of the respective sequencing platforms were used in the participating institutes, mirroring the individual approaches that may be used for routine testing.

Materials and methods
=====================

Samples
-------

A total of 30 tumour samples was collected from 2010 to 2013. All samples were lung adenocarcinomas and each institute contributed 10 samples. Tumours were diagnosed by experienced pathologists and the tumour content was determined by the visual inspection of hematoxylin and eosin (H&E)-stained corresponding sections. The mutation status of the samples was determined previously in routine molecular diagnostics in each institute using conventional methods.

DNA isolation
-------------

All tissue specimens were fixed in neutral-buffered formalin prior to paraffin embedding (FFPE samples). Tumour areas were marked by a pathologist on an H&E-stained slide and DNA was extracted from corresponding unstained 10-*µ*m-thick slides by manual macrodissection. Following treatment with proteinase K, the DNA was isolated by either automated or manual extraction: BioRobot M48 (institute A), the QIAamp DNA FFPE Tissue kit (institute B), QIASymphony SP (institute C) (all from Qiagen, Hilden, Germany) or the Maxwell 16 Research system (institute C; Promega, Madison, WI, USA) following the manufacturer\'s instructions.

DNA quality and quantity
------------------------

The quality and quantity of the isolated DNA samples were assessed by agarose gel electrophoresis and measured fluorimetrically using the Qubit^®^ HS DNA assay (Life Technologies, Darmstadt, Germany) in institute A. The quantity of the isolated DNA was measured spectrophotometrically using the NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) in institute B. In institute C, the DNA content was measured fluorimetrically using the Qubit HS DNA assay (Life Technologies) and using a qPCR-based method (RNaseP Detection system; Life Technologies).

Massive parallel sequencing
---------------------------

### Illumina^®^ MiSeq™ platform

MiSeq (Illumina, San Diego, CA, USA) was used in institute A. The custom-made lung cancer panel consisted of 102 amplicons for the detection of hotspot mutations in 14 lung cancer-related genes. A full list of the covered amplicons is provided in [Table I](#tI-ijmm-36-05-1233){ref-type="table"}. Isolated DNA (20 ng) was amplified with 2 customised Ion AmpliSeq™ Primer Pools for 15 sec at 99°C and 4 min at 60°C for 29 cycles, with an initial denaturating step at 99°C for 2 min. PCR products from the same patient were pooled following treatment with FuPa reagent. Following purification with Agencourt AMPure XP (Beckman Coulter, Brea, CA, USA), the PCR products were incubated with NEXTflex™ DNA Adenylation Mix (Bioo Scientific Corp., Austin, TX, USA). Adapters were supplied by NEXTflex™ DNA Barcodes (Bioo Scientific Corp.). After the bead-mediated size selection, NEXTflex™ PCR Master Mix (Bioo Scientific Corp.) was used for the final PCR amplification at 98°C for 15 sec and 60°C for 1 min for 10 cycles, with an initial denaturating step at 98°C for 2 min. Library products were quantified using a Qubit^®^ 2.0 Fluorometer (Qubit^®^ dsDNA HS kit; Life Technologies), diluted and pooled in equal amounts. A total of 6--8 pM was spiked with 5% PhiX DNA and sequenced using the MiSeq™ reagent kit V2 (300 cycles) (both from Illumina). Data were exported as FASTQ files.

### GS Junior platform

GS Junior (Roche, Basel, Switzerland) was used in institute B. Genomic DNA (10--250 ng) was used for the amplification of EGFR exons 18--21 in a single multiplex reaction using the EGFR 18--21 MASTR assay and the 454 MID kit 1--8 (both from Multiplicom N.V., Niel, Belgium) according to the manufacturer\'s instructions. Libraries were purified, quantified, diluted to a final concentration of 1×10^6^ molecules, multiplexed, clonally amplified by emulsion PCR and sequenced on the GS Junior (Roche) following the manufacturer\'s instructions. Amplicon libraries were sequenced in two runs on 454 GS Junior with 15 samples each.

### PGM Ion Torrent platform

PGM Ion Torrent (Life Technologies) was used in institute C. For library preparation, the multiplex PCR-based Ion Torrent™ AmpliSeq™ technology (Life Technologies) with a custom-made lung cancer panel was used. The panel consisted of 139 primer pairs for the detection of hotspot mutations in 41 lung cancer-related genes. A full list of the covered amplicons is provided in [Table I](#tI-ijmm-36-05-1233){ref-type="table"}. Amplicon library preparation was performed with the Ion AmpliSeq™ Library kit v2.0 using approximately 10 ng of DNA as advised by the manufacturer. The PCR cycling conditions were as follows: initial denaturation: 99°C for 2 min, cycling: 21 cycles of 99°C, 15 sec and 60°C, 4 min. PCR products were partially digested using FuPa reagent as instructed, followed by the ligation of barcoded sequencing adapters (Ion Xpress Barcode Adapters 1--16 kit; Life Technologies). The final library was purified using Agencourt AMPure XP magnetic beads (Beckman Coulter) and quantified using qPCR (Ion Library Quantitation kit) on a StepOne qPCR machine (both from Life Technologies). The individual libraries were diluted to a final concentration of 100 pM and eight to ten libraries were pooled and processed to library amplification on Ion Spheres using an Ion PGM™ Template OT2 200 kit. Unenriched libraries were quality-controlled using Ion Sphere quality control measurement on a Qubit instrument. Following library enrichment (Ion OneTouch ES), the library was processed for sequencing using the Ion Torrent 200 bp sequencing v2 chemistry and the barcoded libraries were loaded onto a single 318 chip.

Data analysis
-------------

### Illumina MiSeq platform

The FASTQ files were aligned against reference NCBI build 37 (hg19) and annotated using a modified version of a previously described method ([@b13-ijmm-36-05-1233]). The resulting BAM files were visualized using the Integrative Genomics Viewer (IGV; <http://www.broadinstitute.org/igv/>). Called variants were then imported into a FileMaker (FileMaker GmbH, Germany) database for further analysis, annotation and reporting. A 5% cut-off for variant calls was used and the results were only interpreted if the coverage was \>100x.

### GS Junior platform

Alignment against reference NCBI build 37 (hg19) and variant calling was carried out using AVA software (Roche). Thresholds for variant calling were set to a minimum allele frequency of 5% with a coverage of at least 100x. All variants were visually inspected using the AVA software (Roche). Annotation of variants was done according to the HGVS nomenclature.

### PGM Ion Torrent platform

Raw data processing, sequence generation and alignment to the reference hg19 genome were conducted using the Torrent Suite software (version 4.0; Life Technologies). Variants were identified using the variant caller plug-in package. For hotspot mutations, a minimum allele frequency of 3% was set and for novel mutations, at least a 5% allele frequency was set as the cut-off level (with coverage \>100x). Annotation of variants was performed with the CLC genomics workbench (version 6.5) followed by the visual inspection of putative mutations using the IGV browser.

Results
=======

DNA concentration
-----------------

DNA extraction from the 30 NSCLC samples was carried out with three different DNA extraction systems and the DNA concentration was measured using individual methods as described above. [Table II](#tII-ijmm-36-05-1233){ref-type="table"} summarises the resulting DNA concentrations. While the DNA concentration ranges measured with the Qubit 2.0 fluorometer in institutes A and C were comparable, the values measured using the NanoDrop 2000c spectrophotometer in institute B were generally higher due to the different principles of measurement. We observed a 1.4- to 856-fold and a 3.9- to 156-fold difference in the concentrations of institute B compared with the concentration values in institutes A and C, respectively with average differences of 133- and 30-fold. Particulary in samples with concentrations below 10 ng/*µ*l, the measurements showed high deviations ([Table II](#tII-ijmm-36-05-1233){ref-type="table"}). Although only minimal amounts of DNA were measured in some samples from institutes A and C, the maximum volume possible was used for the massive parallel analysis for comparative purposes.

Platform comparison summary
---------------------------

The median amplicon sizes for all platforms ranged from 125--345 bp, allowing the amplification of target sequences from degraded DNA obtained from FFPE material ([Table III](#tIII-ijmm-36-05-1233){ref-type="table"}). The number of analysed amplicons ranged from 4 up to 137. Depending on the platform used, the number of samples analysed in one single run varied from 8 up to 48. The maximum number of median reads per sample was approximately 500.000 on the PGM followed by approximately 350.000 on the MiSeq and 5007 reads on the GS Junior. In general, the read coverage for each amplicon was considered to be sufficient for each sample with median values of between 1290 and 7409.

Influence of macrodissection
----------------------------

Manual macrodissection of marked regions on unstained sections was performed to enrich for tumour cells in the extraction. Depending on the strictness of separating tumour cells from normal cells, the resulting allele frequencies for mutant vs. wild-type alleles can vary. This is of particular importance when analysing samples with low tumour cell content or when allele frequencies are expected to be low. Depending on the size of the marked area, the proportion of tumour and normal cells and therewith the allele frequencies could differ in the same sample. This is exemplified in [Fig. 1](#f1-ijmm-36-05-1233){ref-type="fig"}; the area used for DNA extraction was larger in institute B than in institute A. Thus, the corresponding allele frequencies for the *EGFR* mutation of this sample were determined to be 14 and 54%, respectively.

Detection of EGFR mutations
---------------------------

Concerning the expected *EGFR* mutation status, we found concordance in 26 out of 26 samples ([Table IV](#tIV-ijmm-36-05-1233){ref-type="table"}). In all samples, the *EGFR* mutation status was correctly identified by all participants using a 5% threshold for allele frequencies and at least a coverage rate of 100 ([Table IV](#tIV-ijmm-36-05-1233){ref-type="table"}). The *EGFR* mutation status of our sample cohort was comprised of 12 single point mutations, 9 complex exon 19 deletions/insertions and 11 wild-type samples. In three cases, two *EGFR* mutations were present ([Table IV](#tIV-ijmm-36-05-1233){ref-type="table"}, nos. 1, 20 and 21).

In only one case (no. 10), parallel sequencing was unsuccessful due to either failed PCR amplification or insufficient coverage. This case, which could not be analysed by conventional methods previously, was included intentionally to test the limits of parallel sequencing. In three cases (nos. 17, 19 and 25) with limited tumour material, parallel sequencing failed depending on the DNA extraction method. Institute A, using the BioRobot M48, did not get any sequencing results for samples 17 and 25, which was due to high salt concentrations that inhibited the multiplex PCR. Samples 17 and 19 could not be analysed by institute B due to the high degradation of samples and failed amplification.

In 2 out of the 30 samples, minor p.T790M clones of the *EGFR* gene were detected (nos. 12 and 23) by institute A. The underlying mutation was found with 1.03 and 1.42% allele frequency with a coverage of 34779 and 10246, respectively and balanced forward and reverse reads ([Fig. 3](#f3-ijmm-36-05-1233){ref-type="fig"}). A qPCR system (therascreen^®^ EGFR RGQ PCR kit; Qiagen) with a detection limit of 1% allele frequency was used for the verification of originally extracted DNA samples (BioRobot M48; Qiagen), newly extracted DNA samples (Maxwell 16 Research system; Promega) from both samples as well as the corresponding DNA samples from institutes B and C. The minor variants could not be confirmed in any of the DNA samples. Thus, the *EGFR* p.T790M found in the first analysis most likely constitutes a fixation artefact.

Additional mutations and fixation artefacts
-------------------------------------------

Besides the *EGFR* mutations, additional variants were identified by institutes A and C using more comprehensive primer sets ([Table V](#tV-ijmm-36-05-1233){ref-type="table"}). Concordance was found in 15 additional variants, whereas 16 variants could not be confirmed due to the missing inclusion of the respective primers in the individual panels. Seven samples (nos. 1, 4, 8, 13, 20, 24 and 30) showed no additional mutations, which was confirmed by both institutes.

Concordant results were found in the genes *CTNNB1* (no. 22), *PIK3CA* (nos. 19 and 21) and most frequently in *TP53* (nos. 2, 3, 5, 6, 7, 11, 12, 15, 18 and 19). In two samples (nos. 9 and 26), a recurrent *KRAS* p.G12D mutation was identified. Notably, in sample 9 this *KRAS* mutation with a low allele frequency of 2.36 and 5%, respectively, was identified by both institutes, thereby confirming the true nature of this mutation ([Table V](#tV-ijmm-36-05-1233){ref-type="table"}).

Divergent results were discovered in sample no. 29. The average number of reported variants for each sample was 172 for all allele frequencies and 23 for allele frequencies above 5% in institute A. Sample no. 29 showed a markedly higher number of variants (157) following bioinformatic analysis institute A. The sample from institute A had a very low DNA concentration ([Table II](#tII-ijmm-36-05-1233){ref-type="table"}) and the variants were predominantly G\>A or T\>C substitutions. The results included besides other variants different hotspot mutations such as *BRAF* c.1406G\>A, p.G469E \[allele frequency (AF), 51%; coverage (cov), 6813\], *PIK3CA* c.1633G\>A, p.E545K (AF, 18%; cov, 6190) and *NRAS* c.178G\>A, p.G60R (AF, 39%; cov, 2187) ([Table V](#tV-ijmm-36-05-1233){ref-type="table"} and Fig. For verification, the respective regions were reanalysed with Sanger sequencing as previously described ([@b14-ijmm-36-05-1233]). The mutations could not be confirmed and were categorized as fixation artefacts.

Discussion
==========

In routine pathological diagnostics mostly FFPE material is available for molecular characterisation. With decreasing sample sizes and increasing numbers of molecular analyses, a targeted sequencing approach using MPS systems seems to be required. Since it is well known that DNA extracted from FFPE is degraded, with a maximum size of about 350 bp ([@b15-ijmm-36-05-1233]), approaches such as whole genome, transcriptome or exome sequencing are, besides being labour-intensive and expensive, not suitable for routine diagnostics. Targeted sequencing with the focus on hotspot regions is suitable for analysing FFPE material, in a cost-effective and technically feasible way. Comparing the benchtop systems available for parallel sequencing, they show all method-specific advantages and disadvantages. The 454 GS Junior has a low throughput, but generates at the same time long runs ([@b16-ijmm-36-05-1233],[@b17-ijmm-36-05-1233]). The Ion Torrent PGM™ is a cost-saving and fast system, but has a limited accuracy in homopolymeric regions, which also applies to the 454 GS Junior ([@b1-ijmm-36-05-1233],[@b16-ijmm-36-05-1233]). The MiSeq has a very high throughput and low error rates, but the runtime is long ([@b17-ijmm-36-05-1233]) and it needs a higher number of samples per run to be cost efficient.

In this study, in comparing 30 lung cancer samples with three different MPS platforms, we observed good concordance in the detection of mutations using different DNA extraction methods, quantification systems and individually designed primer panels. All institutes analysed 26 out of 26 samples accurately concerning the *EGFR* status.

Independently of the downstream methods used, the crucial step in mutation analyses from tumour material is macrodissection and therewith the selection of the right areas. A tumour burden of 40% is recommended for Sanger sequencing ([@b18-ijmm-36-05-1233]). As MPS is more sensitive than Sanger sequencing, the amount of tumour cells required may be lower ([@b19-ijmm-36-05-1233],[@b20-ijmm-36-05-1233]). Samples with low tumour cell content are at risk of being reported as false-negative. In contrast to our results ([@b21-ijmm-36-05-1233]) found no correlation between H&E-based morphologic assessment of tumour burden and the actual mutant allele frequency. In our cohort, the absolute allele frequencies for certain variants showed differences between the three laboratories, depending mainly on the selection of the macrodissected area. Restricted marking of tumour cells increases the detection thresholds, which may be critical for variants with low allele frequencies. Unfortunately at the same time there is an enhanced risk of \'mispicking\' during the manual dissecting process. The important role of manual macrodissection is also emphasized by Ausch *et al* because the combination of the content of tumour cells and the allele frequency leads to the diagnostic study ([@b22-ijmm-36-05-1233]). We recommend a careful pathologic review of each individual case because the minimum percentage of tumour cells for doubtless results has not yet been defined ([@b23-ijmm-36-05-1233]). From our results, we suggest a tumour cell burden of at least 10%, which can also be reached in small biopsies.

Through the development of minimally invasive techniques biopsy sizes are decreasing. This is in contrast to the ever increasing demands of immunohistochemistry stainings and molecular analyses. Minimally invasive biopsies often deliver insufficient amounts of tissue material for subsequent analyses. We included one extra small tissue sample (no. 10) on purpose, which was originally difficult to analyse by conventional methods, to explore how the different MPS systems would cope with such a sample. None of the institutes were able to extract sufficient DNA for a reliable molecular analysis using next-generation sequencing (NGS) technologies.

In institute A, two further samples could not be analysed due to the high salt concentrations in BioRobot M48 extracts ([@b12-ijmm-36-05-1233]). The multiplex PCR for the library generation was inhibited and samples failed completely. Institute B could not analyse two samples as well due to strong DNA degradation. This can be attributed to the manual extraction method chosen byin institute B as it has been reported that automated nucleic acid extraction ensures a standardisation of sample processing and decreases time and variability in the clinical laboratory ([@b24-ijmm-36-05-1233],[@b25-ijmm-36-05-1233]). Additionally, it is well known that manual extraction delivers less DNA than automated extraction ([@b26-ijmm-36-05-1233]). In this study, a comparison of the total DNA amounts is not possible due to the different systems used for measuring of DNA concentration. In institute C, using the automated QIASymphony SP system, only one sample failed. This extraction system was previously shown to generate DNA extracts with higher quality and concentration \[Heydt et al ([@b12-ijmm-36-05-1233])\].

In FFPE material, non-reproducible sequence artefacts caused by DNA deamination induced by the sample fixation are frequently detected by all sequence analysis methods. The characteristic nucleotide transitions G\>A and T\>C had been found by several groups ([@b27-ijmm-36-05-1233]--[@b29-ijmm-36-05-1233]). Sequence artefacts arising from FFPE DNA are especially problematic when only limited amounts of template DNA are used for PCR amplification \[Wong *et al* ([@b29-ijmm-36-05-1233])\]. In one of our samples, we detected mutations in hotspot regions with the typical C\>T and G\>A exchange which could not be validated by Sanger sequencing although they had sufficient allele frequency and coverage in MPS ([Fig. 2](#f2-ijmm-36-05-1233){ref-type="fig"}).

Since the fixation artefacts are amplified during all PCR-based methods and appear as false-positive variants, it is advisable to reduce the DNA amplification steps during mutational analyses. Hybrid selection methods like Nanostring^®^ or SureSelect (Agilent Technologies) work without a preamplification step. Also, an approach from Udar *et al* where the two DNA strands were processed individually minimises fixation artefacts ([@b30-ijmm-36-05-1233]). Two independent libraries were combined and sequenced on the MiSeq (Illumina) instrument. Variant frequencies were calculated using information from both strands and are narrowed down.

Notably, the KRAS mutation (c.35G\>A, p.G12D) in sample nine, which could also be attributed to a fixation artefact, was identified by two institutes with allele frequencies of 2.36 and 5% confirming the true nature of this mutation ([Table V](#tV-ijmm-36-05-1233){ref-type="table"}). Most of the artefacts appear once but not in duplicates so one solution to detect C\>T (and G\>A) sequence artefacts when using FFPE-DNA is to prepare analysis in duplicates. Verification of such low allele frequencies with an alternative method is a challenge, because most methods (Sanger sequencing, high resolution melting) have a higher detection limit than MPS.

The majority of patients with lung cancer receiving EGFR-tyrosine kinase inhibitor (TKI) therapy acquire resistance after a median of 10--16 months ([@b31-ijmm-36-05-1233]). Intense study in these NSCLCs has identified two major mechanisms of developing resistance to first generation TKIs: secondary resistance mutations within the same gene and \'oncogene kinase switch\' systems with an overlap into another pathway ([@b32-ijmm-36-05-1233]). Also, new sensitive detection methods like MPS have identified a proportion of TKI-naive tumours that carry the secondary resistance mutation p.T790M in the *EGFR* gene; these resistant clones may be selected after exposure to TKI inhibitors ([@b32-ijmm-36-05-1233]--[@b35-ijmm-36-05-1233]). In institute A, two samples (nos. 12 and 23) with minor clones for the *EGFR* resistance mutation p.T790M were found ([Table IV](#tIV-ijmm-36-05-1233){ref-type="table"}). Due to the low allele frequency, validation with Sanger sequencing seemed to be impossible. We therefore used a qPCR approach with a detection limit of 1%. Neither the DNA extracts from institutes B and C, nor the newly prepared or the primary DNA extracts from institute A, showed the resistance mutation (data not shown). Therefore, for the analysis of DNA from FFPE tissues, a general detection limit of 5% seems to balance sensitivity vs. reproducibility.
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![Macrodissection. Tumor cells on H&E-stained slides were marked by experienced pathologists. Manual macrodissection of marked regions in (A) resulted in an AF of 14% whereas manual macrodissection of tissue in (B) resulted in 54% AF. H&E, hematoxylin and eosin; AF, allele frequency.](IJMM-36-05-1233-g00){#f1-ijmm-36-05-1233}

![Fixation artefacts. In our cohort, sample 29 showed a high number of variants after the bioinformatic analysis in institute A. Hotspot mutations in BRAF, NRAS and PIK3CA were selected for validation by Sanger sequencing. The mutations could not be confirmed and were therefore assessed to be fixation artefacts. AF, allele frequency; cov, coverage.](IJMM-36-05-1233-g01){#f2-ijmm-36-05-1233}

![Minor variants. Minor variants could be detected in two out of 30 samples in institute A (nos. 12 and 23). The resistance mutation p.T790M in EGFR was found with 1.03 and 1.42% AF with a coverage of 34779 and 10246. AF, allele frequency; cov, coverage.](IJMM-36-05-1233-g02){#f3-ijmm-36-05-1233}

###### 

Overview of the institute-specific gene panels.

  Chromosome                From (hg19)   To (hg19)   Gene name       Exon
  ------------------------- ------------- ----------- --------------- --------------
  Custom panel Heidelberg                                             
  chr1                      27056234      27056365    ARID1A          2
  chr1                      27057662      27057775    ARID1A          3
  chr1                      27057875      27058001    ARID1A          3
  chr1                      27092899      27093023    ARID1A          10
  chr1                      27094337      27094460    ARID1A          11
  chr1                      27099336      27099464    ARID1A          14
  chr1                      27100275      27100411    ARID1A          17
  chr1                      27105906      27106030    ARID1A          20
  chr1                      27106449      27106570    ARID1A          20
  chr1                      27106750      27106883    ARID1A          20
  chr1                      115256484     115256587   NRAS            3
  chr1                      115258676     115258805   NRAS            2
  chr1                      150549826     150549952   MCL-1           3
  chr1                      150551531     150551670   MCL-1           1
  chr2                      178098765     178098890   NFE2L2          2
  chr3                      41266029      41266147    CTNNB1          3
  chr3                      41266893      41267010    CTNNB1          5
  chr3                      41275089      41275211    CTNNB1          9
  chr3                      178916892     178917000   PIK3CA          2
  chr3                      178921523     178921633   PIK3CA          5
  chr3                      178928050     178928160   PIK3CA          8
  chr3                      178936022     178936106   PIK3CA          10
  chr3                      178938830     178938960   PIK3CA          14
  chr3                      178952038     178952157   PIK3CA          21
  chr3                      181430178     181430283   SOX2            1
  chr3                      181430516     181430649   SOX2            1
  chr4                      1803550       1803636     FGFR3           7
  chr4                      1808277       1808409     FGFR3           16
  chr4                      55131108      55131222    PDGFRA          5
  chr4                      55139749      55139881    PDGFRA          10
  chr4                      55140692      55140818    PDGFRA          11
  chr4                      55141036      55141156    PDGFRA          12
  chr4                      55152001      55152128    PDGFRA          18
  chr4                      55156632      55156764    PDGFRA          22
  chr4                      55592107      55592203    KIT             9
  chr4                      55593595      55593684    KIT             11
  chr4                      153245407     153245522   FBXW7           11
  chr4                      153247237     153247369   FBXW7           10
  chr4                      153249405     153249530   FBXW7           9
  chr5                      1264501       1264634     TERT            11
  chr5                      1293392       1293528     TERT            2
  chr6                      66115100      66115214    EYS             7
  chr6                      66204680      66204810    EYS             5
  chr7                      55241602      55241732    EGFR            18
  chr7                      55242411      55242544    EGFR            19
  chr7                      55248974      55249100    EGFR            20
  chr7                      55259416      55259546    EGFR            21
  chr7                      92300724      92300853    CDK6            5
  chr7                      92403995      92404124    CDK6            3
  chr7                      116411944     116412066   MET             14
  chr7                      116417426     116417508   MET             16
  chr7                      140453110     140453232   BRAF            15
  chr7                      140481387     140481511   BRAF            11
  chr8                      38275705      38275835    FGFR1           10
  chr8                      38282107      38282241    FGFR1           7
  chr8                      128751156     128751293   MYC             2
  chr8                      128752956     128753086   MYC             3
  chr9                      5069993       5070100     JAK2            12
  chr9                      5073678       5073788     JAK2            14
  chr9                      5126715       5126797     JAK2            25
  chr9                      21970912      21971032    CDKNA2          2
  chr9                      21971086      21971218    CDKNA2          2
  chr9                      21974672      21974792    CDKNA2          1
  chr9                      139401722     139401834   NOTCH1          22
  chr9                      139404170     139404306   NOTCH1          18
  chr9                      139412260     139412400   NOTCH1          8
  chr9                      139413034     139413159   NOTCH1          6
  chr10                     89624207      89624322    PTEN            1
  chr10                     89685258      89685374    PTEN            3
  chr10                     89692864      89692987    PTEN            5
  chr10                     89711806      89711936    PTEN            6
  chr10                     89717622      89717747    PTEN            7
  chr10                     89720778      89720902    PTEN            8
  chr10                     123256020     123256129   FGFR2           13
  chr10                     123279495     123279622   FGFR2           7
  chr11                     533800        533929      HRAS            3
  chr11                     534220        534349      HRAS            2
  chr11                     69456096      69456216    CCND1           1
  chr11                     69458624      69458747    CCND1           3
  chr11                     119103162     119103275   CBL             2
  chr11                     119148912     119149006   CBL             8
  chr11                     119149215     119149290   CBL             9
  chr12                     25380249      25380348    KRAS            3
  chr12                     25398183      25398310    KRAS            2
  chr12                     69210596      69210679    MDM2            4
  chr12                     69233038      69233165    MDM2            11
  chr13                     48881433      48881526    RB1             2
  chr13                     48916793      48916902    RB1             3
  chr13                     48923124      48923208    RB1             6
  chr13                     48951050      48951160    RB1             13
  chr13                     48954320      48954437    RB1             16
  chr13                     48955427      48955539    RB1             17
  chr13                     49027105      49027191    RB1             18
  chr13                     49033834      49033935    RB1             20
  chr13                     49037844      49037955    RB1             21
  chr13                     49039144      49039221    RB1             22
  chr13                     49039304      49039410    RB1             23
  chr14                     36987081      36987213    NKX-2.1         2
  chr14                     36988227      36988351    NKX-2.1         1
  chr14                     105246470     105246589   AKT1            3
  chr17                     7573886       7574019     TP53            10
  chr17                     7576836       7576950     TP53            9
  chr17                     7577028       7577157     TP53            8
  chr17                     7577492       7577629     TP53            7
  chr17                     7578180       7578289     TP53            6
  chr17                     7578425       7578555     TP53            5
  chr17                     7579278       7579397     TP53            4
  chr17                     7579454       7579566     TP53            4
  chr17                     37880169      37880287    ERBB2           19
  chr17                     37880958      37881089    ERBB2           20
  chr18                     48581196      48581323    SMAD4           5
  chr18                     48584702      48584826    SMAD4           7
  chr18                     48591813      48591934    SMAD4           9
  chr18                     48604680      48604811    SMAD4           12
  chr19                     1206977       1207113     STK11           1
  chr19                     1218379       1218488     STK11           2
  chr19                     1220390       1220504     STK11           4
  chr19                     1220594       1220684     STK11           5
  chr19                     1221205       1221340     STK11           6
  chr19                     1223020       1223155     STK11           8
  chr19                     10599879      10600011    KEAP1           5
  chr19                     10600372      10600496    KEAP1           4
  chr19                     10602263      10602390    KEAP1           3
  chr19                     10602579      10602708    KEAP1           3
  chr19                     10602796      10602912    KEAP1           3
  chr19                     10610088      10610218    KEAP1           2
  chr19                     10610289      10610416    KEAP1           2
  chr19                     10610465      10610599    KEAP1           2
  chr19                     11094812      11094945    SMARCA4         2
  chr19                     11136088      11136220    SMARCA4         22
  chr19                     11138426      11138556    SMARCA4         23
  chr19                     11141448      11141561    SMARCA4         25
  chr19                     11144042      11144179    SMARCA4         26
  chr19                     30308024      30308156    CCNE1           5
  chr19                     30313134      30313262    CCNE1           10
  chrX                      47028755      47028888    RBM10           3
  chrX                      47034396      47034523    RBM10           5
  chrX                      63411268      63411399    FAM123B/AMER1   1
  chrX                      63412836      63412964    FAM123B/AMER1   1
  Custom panel Cologne                                                
  chr1                      115256352     115256453   NRAS            3
  chr1                      115256453     115256550   NRAS            3
  chr1                      115256550     115256672   NRAS            3
  chr1                      115258676     115258798   NRAS            2
  chr1                      162688829     162688951   DDR2            3
  chr1                      162722872     162722995   DDR2            4
  chr1                      162724359     162724466   DDR2            5
  chr1                      162724466     162724586   DDR2            5
  chr1                      162724586     162724687   DDR2            5
  chr1                      162724850     162724967   DDR2            6
  chr1                      162724967     162725094   DDR2            6
  chr1                      162725447     162725572   DDR2            7
  chr1                      162729566     162729694   DDR2            8
  chr1                      162729681     162729782   DDR2            8
  chr1                      162730973     162731107   DDR2            9
  chr1                      162731107     162731197   DDR2            9
  chr1                      162731197     162731276   DDR2            9
  chr1                      162735765     162735879   DDR2            10
  chr1                      162736904     162737029   DDR2            11
  chr1                      162737029     162737154   DDR2            11
  chr1                      162740090     162740201   DDR2            12
  chr1                      162740201     162740327   DDR2            12
  chr1                      162741756     162741887   DDR2            13
  chr1                      162741887     162742002   DDR2            13
  chr1                      162742002     162742088   DDR2            13
  chr1                      162743204     162743301   DDR2            14
  chr1                      162743301     162743421   DDR2            14
  chr1                      162745384     162745513   DDR2            15
  chr1                      162745513     162745634   DDR2            15
  chr1                      162745915     162746038   DDR2            16
  chr1                      162746038     162746162   DDR2            16
  chr1                      162748317     162748432   DDR2            17
  chr1                      162748432     162748519   DDR2            17
  chr1                      162749866     162749977   DDR2            18
  chr1                      162749977     162750066   DDR2            18
  chr2                      29432650      29432776    ALK             25
  chr2                      29436843      29436974    ALK             24
  chr2                      29443565      29443688    ALK             23
  chr2                      29443688      29443772    ALK             23
  chr2                      29445200      29445332    ALK             22
  chr2                      29445369      29445489    ALK             21
  chr3                      41266072      41266193    CTNNB1          3
  chr3                      178935940     178936023   PIK3CA          9
  chr3                      178936023     178936105   PIK3CA          9
  chr3                      178936092     178936180   PIK3CA          9
  chr3                      178951824     178951942   PIK3CA          20
  chr3                      178951942     178952063   PIK3CA          20
  chr3                      178952063     178952155   PIK3CA          20
  chr7                      55241596      55241679    EGFR            18
  chr7                      55241679      55241800    EGFR            18
  chr7                      55242411      55242539    EGFR            19
  chr7                      55248984      55249117    EGFR            20
  chr7                      55249117      55249200    EGFR            20
  chr7                      55259367      55259486    EGFR            21
  chr7                      55259484      55259567    EGFR            21
  chr7                      116411701     116411801   cMET            intron 13/14
  chr7                      116411801     116411909   cMET            14
  chr7                      116411894     116411998   cMET            intron 13/14
  chr7                      116411998     116412072   cMET            14
  chr7                      140453023     140453099   BRAF            15
  chr7                      140453099     140453224   BRAF            15
  chr7                      140481297     140481387   BRAF            11
  chr7                      140481387     140481511   BRAF            11
  chr10                     89624207      89624322    PTEN            1
  chr10                     89653745      89653817    PTEN            2
  chr10                     89653816      89653930    PTEN            2
  chr10                     89685258      89685374    PTEN            3
  chr10                     89690819      89690917    PTEN            4
  chr10                     89692713      89692819    PTEN            5
  chr10                     89692819      89692920    PTEN            5
  chr10                     89692920      89693032    PTEN            5
  chr10                     89711802      89711928    PTEN            6
  chr10                     89711917      89712018    PTEN            6
  chr10                     89717580      89717695    PTEN            7
  chr10                     89717694      89717792    PTEN            7
  chr10                     89720692      89720768    PTEN            8
  chr10                     89720769      89720842    PTEN            8
  chr10                     89724948      89725061    PTEN            9
  chr10                     89725058      89725147    PTEN            9
  chr10                     89725207      89725320    PTEN            9
  chr12                     25380167      25380240    KRAS            3
  chr12                     25380240      25380357    KRAS            3
  chr12                     25398183      25398304    KRAS            2
  chr12                     25398304      25398379    KRAS            2
  chr14                     105246406     105246502   AKT1            4
  chr14                     105246500     105246583   AKT1            4
  chr15                     66727356      66727487    MAP2K1          2
  chr15                     66727487      66727602    MAP2K1          2
  chr17                     7577017       7577142     TP53            8
  chr17                     7577140       7577233     TP53            8
  chr17                     7577392       7577509     TP53            7
  chr17                     7577508       7577611     TP53            7
  chr17                     7578141       7578234     TP53            6
  chr17                     7578234       7578362     TP53            6
  chr17                     7578310       7578425     TP53            5
  chr17                     7578425       7578555     TP53            5
  chr17                     7579278       7579385     TP53            4
  chr17                     7579385       7579502     TP53            4
  chr17                     7579502       7579590     TP53            4
  chr17                     37880155      37880283    HER2            19
  chr17                     37880960      37881074    HER2            20
  chr17                     37881074      37881206    HER2            20

###### 

DNA concentration.

  Sample no.   Institute A (ng/*µ*l)   Institute B (ng/*µ*l)   Institute C (ng/*µ*l)
  ------------ ----------------------- ----------------------- -----------------------
  1            31                      362.9                   20.8
  2            2.9                     7.84                    0.85
  3            3.32                    109.16                  7.81
  4            0.1                     4.03                    0.41
  5            12.8                    186.49                  11.7
  6            7.5                     14.92                   1.15
  7            16.6                    374.76                  4.55
  8            2.44                    24.24                   1.48
  9            26.6                    504.4                   44.8
  10           0.1                     3.61                    \<0.5
  11           10.3                    26.1                    3.42
  12           5.7                     266.83                  2.36
  13           8.06                    11.58                   2.94
  14           4.56                    21.62                   1.18
  15           2.06                    28.72                   4.94
  16           2.7                     15.64                   1.25
  17           1.29                    25.68                   3.58
  18           3.78                    17.32                   1.99
  19           0.1                     19.24                   4.3
  20           8.8                     204.08                  1.3
  21           0.1                     1.3                     0.1
  22           18.4                    470.92                  12.2
  23           0.83                    204.61                  6.08
  24           0.97                    52.5                    5.34
  25           0.16                    103.01                  2.85
  26           0.3                     103.01                  8.52
  27           0.24                    60.02                   1.31
  28           0.1                     85.57                   1.06
  29           0.1                     47.74                   0.7
  30           0.1                     56.77                   4.2

DNA extraction from 30 non-small cell lung cancer (NSCLC) samples was carried out with three different DNA extraction systems from Qiagen: BioRobot M48, QIA Symphony SP as well as manual extraction. After the extraction, concentration was measured with the Qubit 2.0 fluorometer in institutes A and C, or with the NanoDrop 2000c spectrophotometer in institute B.

###### 

Sequencing statistics.

                             MiSeq™      PGM Ion Torrent™   GS Junior
  -------------------------- ----------- ------------------ -----------
  No. of Amplicons           102         137                4
  Median amplicon size       150 bp      125 bp             345 bp
  Samples/run                48          8--10              15
  Median reads/sample        \~350.000   \~ 500.000         5007
  Median coverage/amplicon   7409x       2500x              1290x

Overview of the different massive parallel sequencing (MPS) platforms. bp, base pairs.

###### 

EGFR mutation status.

  Case   Expected result      A             B      C      Tumor cell content   A             B       C      A AF%     B AF%   C AF%
  ------ -------------------- ------------- ------ ------ -------------------- ------------- ------- ------ --------- ------- -------
  1      p.G719A              √             √      √      50                   13936         4917    3001   20        15      24
  1      p.V834L              √             √      √      50                   9112          4917    4829   17        18      22
  2      p.L838R              √             √      √      80                   1430          10143   5885   17        17      17
  3      p.E746_A750del       √             √      √      60                   10584         3379    9216   79        45      44
  4      p.E746_A750del       √             √      √      10                   1102          512     5116   23        18      22
  5      wt                   √             √      √      90                   wt            wt      wt                       
  6      wt                   √             √      √      70                   wt            wt      wt                       
  7      wt                   √             √      √      60                   wt            wt      wt                       
  8      wt                   √             √      √      30                   wt            wt      wt                       
  9      wt                   √             √      √      30                   wt            wt      wt                       
  10     --                   n.a.          n.a.   n.a.   80                   n.a.          n.a.    n.a.                     
  11     p.E746_A750del       √             √      √      60                   9562          5020    1947   67        60      49
  12     p.L858R              √ + p.T790M   √      √      50                   29429/34779   8291    2820   28/1.03   21      12
  13     p.E746_A750del       √             √      √      40                   9936          11132   2820   31        29      25
  14     p.L858R              √             √      √      30                   35355         6911    5693   36        33      13
  15     p.L858R              √             √      √      50                   14143         1381    3407   31        41      31
  16     p.E746_A750del       √             √      √      70                   11546         1472    1975   34        51      33
  17     p.L858R              n.a.          n.a.   √      70                   n.a.          n.a.    3336   n.a.      n.a.    20
  18     p.E746_A750del       √             √      √      n.d.                 4179          406     1521   54        14      10
  19     p.L747_A751delinsP   √             n.a.   √      70                   7445          n.a.    1585   75        n.a.    54
  20     p.L747_P753delinsS   √             √      √      80                   8010          5816    4221   75        59      49
  20     p.A755D              √             √      √      80                   7297          5816    4221   74        59      59
  21     p.E709A              √             √      √      80                   716           3273    4662   23        24      22
  21     p.G719S              √             √      √      80                   2102          3273    4640   9         24      20
  22     p.E746_A750del       √             √      √      50                   8391          33615   1968   62        56      50
  23     p.L858R              √ + p.T790M   √      √      30                   20413/10246   11389   1994   27/1.42   20      18
  24     p.L858R              √             √      √      30                   9794          16509   1714   34        26      30
  25     wt                   n.a.          √      √      60                   wt            wt      wt                       
  26     wt                   √             √      √      60                   wt            wt      wt                       
  27     wt                   √             √      √      70                   wt            wt      wt                       
  28     wt                   √             √      √      60                   wt            wt      wt                       
  29     wt                   √             √      √      70                   wt            wt      wt                       
  30     wt                   √             √      √      n.d.                 wt            wt      wt                       

Concerning the epidermal growth factor receptor (EGFR) mutation status, we found concordance in 26/26 samples. The mutation status was analysed previously with conventional methods. Institute A found two resistance mutations in samples 12 and 23. AF%, allele frequency; hook, concordant EGFR result; n.a., not analysable, n.d., not determined; wt, wild-type.

###### 

Additional variations.

  Case   Gene      Nucleotide change   AA change   AF A (%)    AF C (%)
  ------ --------- ------------------- ----------- ----------- ----------
  1      --        --                  --          --          --
  2      TP53      c.469G\>T           p.V157F     80          79
  3      TP53      c.637C\>T           p.R213\*    79          34
  4      --        --                  --          --          --
  5      NKX2.1    c.515A\>C           p.Q172P     n.i.        23
         RB1       c.2267delA          p.Y756fs    n.i.        91
         TP53      c.733G\>T           p.G245C     87          91
  6      TP53      c.641A\>G           p.H214R     33          23
  7      TP53      c.830G\>T           p.C277F     23          44
  8      --        --                  --          --          --
  9      KRAS      c.35G\>A            p.G12D      2           5
  10                                               n.a.        n.a.
  11     TP53      c.1073C\>T          p.P295S     1           5
         JAK3      c.2164G\>A          p.V722I     n.i.        37
  12     TP53      c.610G\>T           p.E204\*    7           25
  13     --        --                  --          --          --
  14     ATM       c.2572T\>C          p.F858L     n.i.        66
  15     TP53      c.913A\>T           p.K305      26          20
         KIT       c.1621A\>C          p.M541L     n.i.        57
  16     SMO       c.979G\>A           p.A327T     n.i.        45
  17     --        --                  --          n.a.        --
  18     TP53      c.530C\>G           p.P177R     26          8
  19     TP53      c.725G\>A           p.C242Y     81          34
         TP53      c.555C\>G           p.S185R     73          n.i.
         KIT       c.1621A\>C          p.M541L     n.i.        78
         PIK3CA    c.1633G\>A          p.E545K     44          4
  20     --        --                  --          --          --
  21     PIK3CA    c.1624G\>A          p.E542K     18          17
  22     CTNNB1    c.98C\>G            p.S33C      33          31
  23     NOTCH1    c.3604C\>T          p.P1202S    n.i.        5
         RBM10     c.79delG            p.G27fs     n.i.        17
  24     --        --                  --          --          --
  25     SMARCA4   c.3634G\>A          p.E1212K    n.i./n.a.   5
         KRAS      c.35G\>A            p.G12D      n.a.        10
  26     KRAS      c.35G\>A            p.G12D      26          29
  27     KEAP1     c.1426G\>T          p.G476W     n.i.        45
         MAP2K1    c.171G\>T           p.K57N      45          n.i.
  28     CDK6      c.584G\>T           p.S195I     n.i.        13
         CDKN2A    c.253C\>T           p.Q85       n.i.        6
  29     HRAS      c.59C\>T            p.T20I      n.i.        5
         BRAF      c.1406G\>A          p.G469E     FA          --
         NRAS      c.178G\>A           p.G60R      FA          --
         PIK3CA    c.1633G\>A          p.E545K     FA          --
  30     --        --                  --          --          --

Besides the epidermal growth factor receptor (*EGFR*) mutations, additional mutations could be identified with the extended primer sets used in institutes A and C. Concordance was found in 15 additional variations whereas 16 variants could not be confirmed by the other institute due to missing primer panel inclusion. Fixation artefacts were observed in sample 29. AA, amino acid; AF, allele frequency; FA, fixation artefact; n.a., not analysable; n.i., not included in primer panel; -, no variant found.
